Skip to content

The Effect of Bacillus Calmette-Guerin Polysaccharide Nucleic Acid (BCG-PSN) Acupoint Injection Combining Qingfei Sanjie Decoction on Small Pulmonary Nodules

The Effect of Bacillus Calmette-Guerin Polysaccharide Nucleic Acid (BCG-PSN) Acupoint Injection Combining Qingfei Sanjie Decoction on Small Pulmonary Nodules

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400080776
Enrollment
Unknown
Registered
2024-02-06
Start date
2023-01-06
Completion date
Unknown
Last updated
2024-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Nodule

Interventions

Acupoint injection and Chinese medicine group:BCG-PSN acupoint injection and Qingfei Sanjie decoction
Acupoint injection group:BCG-PSN acupoint injection
Chinese medicine group:Qingfei Sanjie decoction
Waiting for treatment group:Waiting for treatment

Sponsors

The Third Affiliated Hospital of Zhejiang Chinese Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: ? The pulmonary CT shows focal, circular, dense solid or solid pulmonary shadows with a diameter of 5~10mm, which may be isolated or multiple, without atractasis, hilar lymph node enlargement, and pleural effusion. ? Without obvious signs of malignant tumor, we will choose the patient if he or she meets any one item of the following items: i. Patients with no rapid growth in the size of pulmonary nodules in the last 3 months, and doctors of the imaging department, respiratory department, and thoracic surgery departmentall all believe that no further treatment is necessary and follow-up is going on. ii. Thin slice CT and PET-CT shows no obvious signs of malignant tumor; iii. Non-surgical or surgical biopsy results shows no malignant lesions; ? 18 =age =75; gender no limit; ? Patients have high compliance and sign informed consent.

Exclusion criteria

Exclusion criteria: ? Patients with serious primary diseases of cardiovascular, cerebrovascular, liver, kidney and blood system; ? Patients with active tuberculosis and other infectious diseases; ? Patients with mental diseases or other reasons who could not cooperate with the researcher; ? Pregnant or lactating women; ? Paitents with missing contact information or incomplete case information.

Design outcomes

Secondary

MeasureTime frame
Clinical efficacy rate;Risk rate of malignancy;Recurrence rate;Anxiety and depression degree;

Primary

MeasureTime frame
Nodule size;

Countries

China

Contacts

Public ContactChen Lifang

The Third Affiliated Hospital of Zhejiang Chinese Medical University

clfang@163.com+86 139 5715 7278

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026